Comment from Biocom

Summary: Biocom, an advocacy organization representing California's life science sector, supports the FDA's effort to modernize and harmonize the SUPAC guidances. They argue for a consolidated, risk-based framework that incorporates modern manufacturing technologies (like PAT and RTRT), aligns with international ICH standards, and provides practical decision tools to reduce regulatory burden.